Citations

Showing 10 of 108135 citations.

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
Menghrajani, Kamal , Gomez-Arteaga, Alexandra , Madero‐Marroquin, Rafael , Zhang, Mei‐Jie , Bo-Subait, Khalid, Sánchez, J. Ortiz, Wang, Hailin , Aljurf, Mahmoud , Assal, Amer , Bejanyan, Nelli , Bredeson, Christopher , Byrne, Michael , Castillo, Paul , Černý, Jan , Ciurea, Stefan O. , DeFilipp, Zachariah , Farhadfar, Nosha , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Gowda, Lohith , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Kanakry, Christopher G. , Khimani, Farhad , Krem, Maxwell M. , Liu, Hongtao , Martino, Rodrigo , Michelis, Fotios V. , Nathan, Sunita , Rizzieri, David A. , Rowe, Jacob M. , Seo, Sachiko , Sharma, Akshay , Solh, Melhem , Üstün, Celalettin , Verdonck, Leo F. , Litzow, Mark R. , Weisdorf, Daniel J. , Zhang, Yanming , Tallman, Martin S. , Saber, Wael , Bacher, Ulrike , Bejanyan, Nelli , Bhatt, Vijaya Raj , Cerny, Jan , Chhabra, Saurabh , DeFilipp, Zachariah , Gadalla, Shahinaz M , Gale, Robert P , Hashmi, Shahrukh K , Hildebrandt, Gerhard C , Kansagra, Ankit , Krem, Maxwell M , Lazarus, Hillard M , Liu, Hongtao , Martino, Rodrigo , Michelis, Fotios V , Nishihori, Taiga , Olsson, Richard F , Reshef, Ran , Rizzieri, David A , Savani, Bipin N , Seo, Sachiko , Sharma, Akshay , Ustun, Celalettin , Hourigan, Christopher S , Sandmaier, Brenda M , Litzow, Mark R. , Weisdorf, Dan , Assal, Amer , Badawy, Sherif M. , Bhatt, Vijaya Raj , Chhabra, Saurabh , Gale, Robert Peter , Grunwald, Michael R. , Kansagra, Ankit , Lazarus, Hillard M. , Nishihori, Taiga , Olsson, Richard F. , Reshef, Ran , Savani, Bipin N. , Hourigan, Christopher S. , Kebriaei, Partow

Mayo Clinic

Blood Advances | September 22, 2021 | Volume: 6 | Issue: 3 | Pages: 828-847

10.1182/bloodadvances.2021004881 | PMID 34551064 Get It

Abstract Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. An adjusted multivariable analysis detected an increased risk of relapse for patients with KMT2A-rearranged or adverse-risk AML as compared to those with intermediate-risk disease (hazards ratio [HR], 1.27; P = .01; HR, 1.71; P < .001, respectively). Leukemia-free survival was similar for patients with KMT2A rearrangement or adverse risk (HR, 1.26; P = .002, and HR, 1.47; P < .001), as was overall survival (HR, 1.32; P < .001, and HR, 1.45; P < .001). No differences in outcome were detected when patients were stratified by KMT2A fusion partner. This study is the largest conducted to date on post-HCT outcomes in AML, with manually curated cytogenetics used for risk stratification. Our work demonstrates that risk classification at diagnosis remains predictive of post-HCT outcomes in AML. It also highlights the critical need to develop novel treatment strategies for patients with KMT2A-rearranged and adverse-risk disease.
Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis
Garinis, Angela C. , Poling, Gayla L. , Konrad‐Martin, Dawn , Hullar, Timothy E. , Burrows, Holly , Chisholm, Jennifer , Custer, Amy , Hawe, Laura Dreisbach, Hunter, Lisa L. , Marras, Theodore K. , Ortiz, Candice E., Petersen, Lucretia , Winthrop, Kevin , Zettner, Erika M., Clark, Khaya D. , Hungerford, Michelle, Vachhani, Jay J., Brewer, Carmen C. , Steyger, Peter S , Clark, Khaya , Poling, Gayla L , Rubenstein, Ronald C. , Baguley, David

Mayo Clinic

American Journal of Audiology | September 22, 2021 | Volume: 30 | Issue: 3S | Pages: 800-809

10.1044/2021_aja-21-00031 | PMID 34549989 Get It

Purpose Specific classes of antibiotics, such as aminoglycosides, have well-established adverse events producing permanent hearing loss, tinnitus, and balance and/or vestibular problems (i.e., ototoxicity). Although these antibiotics are frequently used to treat pseudomonas and other bacterial infections in patients with cystic fibrosis (CF), there are no formalized recommendations describing approaches to implementation of guideline adherent ototoxicity monitoring as part of CF clinical care. Method This consensus statement was developed by the International Ototoxicity Management Working Group (IOMG) Ad Hoc Committee on Aminoglycoside Antibiotics to address the clinical need for ototoxicity management in CF patients treated with known ototoxic medications. These clinical protocol considerations were created using consensus opinion from a community of international experts and available evidence specific to patients with CF, as well as published national and international guidelines on ototoxicity monitoring. Results The IOMG advocates four clinical recommendations for implementing routine and guideline adherent ototoxicity management in patients with CF. These are (a) including questions about hearing, tinnitus, and balance/vestibular problems as part of the routine CF case history for all patients; (b) utilizing timely point-of-care measures; (c) establishing a baseline and conducting posttreatment evaluations for each course of intravenous ototoxic drug treatment; and (d) repeating annual hearing and vestibular evaluations for all patients with a history of ototoxic antibiotic exposure. Conclusion Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. Supplemental Material https://doi.org/10.23641/asha.16624366
Identification of Risk Factors for Acute Kidney Injury from Intravenous Ketorolac in Geriatric Trauma Patients
Hall, Scott T. , Mangram, Alicia J. , Barletta, Jeffrey F.

Mayo Clinic

World Journal of Surgery | September 22, 2021 | Volume: 46 | Issue: 1 | Pages: 98-103

10.1007/s00268-021-06320-z | PMID 34553259 Get It

AbstractBackgroundKetorolac is an effective analgesic but the potential for acute kidney injury (AKI) is concerning, particularly in geriatric “G‐60 trauma” patients. The objectives of this study are to report the incidence of AKI in patients who receive ketorolac, identify risk factors for AKI, and develop a risk factor‐guided algorithm for safe utilization.MethodsThis retrospective cohort study included trauma patients age 60 years and older who received intravenous ketorolac. The primary endpoint was the incidence of AKI.ResultsAmong 316 patients evaluated, the incidence of AKI was 2.5%. Patients with AKI received more nephrotoxins, had more comorbidities, and higher use of loop diuretics or vasopressors. Loop diuretic therapy and number of comorbidities were independent predictors of AKI.ConclusionsRisk for AKI with ketorolac was low, being more prevalent with comorbidities or receipt of loop diuretics.
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Brown, Patrick A. , Aoun, Patricia, Boyer, Michael W., Burke, Patrick W. , Dinner, Shira, Fathi, Amir T. , Kirby, Suzanne, Liedtke, Michaela , Litzow, Mark R. , Luger, Selina M. , Maness, Lori J., Massaro, Stephanie, Mattison, Ryan J. , May, William , Oluwole, Olalekan O. , Park, Jae H. , Uy, Geoffrey L. , Vusirikala, Madhuri , Wieduwilt, Matthew J. , Lynn, Beth, Berardi, Ryan A., Freedman-Cass, Deborah A., Campbell, Mallory, Oluwole, Olalekan O , Uy, Geoffrey , Shah, Bijal , Advani, Anjali S. , DeAngelo, Daniel J. , Gauthier, Jordan , Jain, Nitin , Logan, Aaron C , Przespolewski, Amanda , Rangaraju, Sravanti , Rubnitz, Jeffrey E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 22, 2021 | Volume: 19 | Issue: 9 | Pages: 1079-1109

10.6004/jnccn.2021.0042 | PMID 34551384 Get It

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.
Finding the Middle Ground with the Clinical Laboratory’s Role in SARS-CoV-2 Genomic Surveillance
Graf, Erin H. , Graf, Erin H

Mayo Clinic

Journal of Clinical Microbiology | September 22, 2021 | Volume: 59 | Issue: 12 | Pages: No page available

10.1128/jcm.01816-21 | PMID 34550811 Get It

Continued replacement of the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages, and associated surges, highlights the importance of genomic surveillance to identify the next possible threats. Despite concerted efforts between clinical laboratories and public health to generate sequence data, the United States has lagged in percentage of SARS-CoV-2 cases sequenced.
A Longitudinal Examination of Quality of Life of Older Adults with Complicated Grief Receiving Accelerated Resolution Therapy
Mason, Tina M. , Szalacha, Laura A. , Tofthagen, Cindy , Buck, Harleah G. , Tofthagen, Cindy S

Mayo Clinic

Journal of Palliative Medicine | September 22, 2021 | Volume: 25 | Issue: 1 | Pages: 119-123

10.1089/jpm.2021.0267 | PMID 34551271 Get It

Sex Differences in Treatment Strategy and Adverse Outcomes Among Patients 75 and Older With Atrial Fibrillation in the MarketScan Database
Subramanya, Vinita , Claxton, J’Neka S. , MacLehose, Richard F. , Norby, Faye L. , Lutsey, Pamela L. , Chen, Lin Y. , Chamberlain, Alanna M. , Alonso, Álvaro

Mayo Clinic

No container title available | September 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-852138/v1 Get It

Abstract Background: Women with atrial fibrillation (AF) experience greater symptomatology, worse quality of life, and have a higher risk of stroke as compared to men, but are less likely to receive rhythm control treatment. Whether these differences exist in elderly patients with AF, and whether sex modifies the effectiveness of rhythm versus rate control therapy has not been assessed.Methods: We studied 135,850 men and 139,767 women aged ≥75 years diagnosed with AF in the MarketScan Medicare database between 2007-2015. Anticoagulant use was defined as use of warfarin or a direct oral anticoagulant. Rate control was defined as use of rate control medication or atrioventricular node ablation. Rhythm control was defined by use of anti-arrhythmic medication, catheter ablation or cardioversion. We used multivariable Poisson and Cox regression models to estimate the association of sex with treatment strategy and to determine whether the association of treatment strategy with adverse outcomes (bleeding, heart failure and stroke) differed by sex. Results: At the time of AF, women were on average (SD) 83.8 (5.6) years old and men 82.5 (5.2) years, respectively. Compared to men, women were less likely to receive an anticoagulant or rhythm control treatment. Rhythm control (vs. rate) was associated with a greater risk for heart failure with a significantly stronger association in women (HR women = 1.41, 95%CI 1.34-1.49; HR men= 1.21, 95%CI 1.15-1.28, p <0.0001 for interaction). No sex differences were observed for the association of treatment strategy with the risk of bleeding or stroke. Conclusion: Sex differences exist in the treatment of AF among patients aged 75 years and older. Women are less likely to receive an anticoagulant and rhythm control treatment. Women were also at a greater risk of experiencing heart failure as compared to men, when treated with rhythm control strategies for AF. Efforts are needed to enhance use AF therapies among women. Future studies will need to delve into the mechanisms underlying these differences.
A Simplified Method for the Diagnosis of Constrictive Pericarditis in the Cardiac Catheterization Laboratory
Jain, C. Charles , Miranda, William R. , Sabbagh, Abdallah El , Nishimura, Rick A.

Mayo Clinic

JAMA Cardiology | September 22, 2021 | Volume: 7 | Issue: 1 | Pages: 100

10.1001/jamacardio.2021.3478 | PMID 34550314 Get It

Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer
Aggarwal, Ritesh K. , Luchtel, Rebecca A. , Machha, Venkata R. , Tischer, Alexander , Zou, Yiyu , Ashai, Nadia , Ramachandra, Nandini , Albanese, Joseph , Yang, Jung‐In , Aluri, Srinivas , Gordon, Shanisha, Aboumohamed, Ahmed , Gartrell, Benjamin A. , Hafizi, Sassan , Pullman, James , Shenoy, Niraj , Yang, Jung-In , Aluri, Srinivas , Aboumohamed, Ahmed , Hafizi, Sassan , Shenoy, Niraj , Tischer, Alexander , Pradhan, Kith , Wang, Xiaoyang

Mayo Clinic

Proceedings of the National Academy of Sciences | September 22, 2021 | Volume: 118 | Issue: 39 | Pages: No page available

10.1073/pnas.2106947118 | PMID 34551979 Get It

Significance This study demonstrates that underexpression of succinate dehydrogenase (SDH) subunits resulting in accumulation of oncogenic succinate is a common, adverse, epigenetic modulating feature in clear cell renal cell carcinoma (ccRCC), during pathogenesis and progression. The study sheds light on the mechanisms of down-regulation of SDH subunits in ccRCC and deciphers the consequent oncogenic effects. It shows that functional SDH deficiency is a common feature of ccRCC (∼80% of all kidney cancers), and not just limited to the 0.05 to 0.5% of kidney cancers with germline SDH mutations.
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021
Walter, Louise C. , Browner, Ilene , Clifton, Katherine , Cohen, Harvey Jay, Extermann, Martine , Gross, Cary P. , Gupta, Sumati , Hollis, Genevieve, Keating, Nancy L. , Koll, Thuy T., McKoy, June M. , Misra, Sumi, Moon, Dominic H. , Owusu, Cynthia , Rosko, Ashley , Russell, Marcia M. , Sedrak, Mina S. , Siddiqui, Fareeha, Stella, Amy, Stirewalt, Derek L. , Tew, William P. , Hollinger, Liz, George, Giby V. , Sundar, Hema, Dotan, Efrat , Clifton, Katherine , Hubbard, Joleen M. , Jagsi, Reshma , Kessler, Elizabeth , Korc‐Grodzicki, Beatriz , O’Connor, Tracey L. , Sedrak, Mina S. , Subbiah, Ishwaria M. , Williams, Grant R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 22, 2021 | Volume: 19 | Issue: 9 | Pages: 1006-1019

10.6004/jnccn.2021.0043 | PMID 34551388 Get It

The NCCN Guidelines for Older Adult Oncology address specific issues related to the management of cancer in older adults, including screening and comprehensive geriatric assessment (CGA), assessing the risks and benefits of treatment, preventing or decreasing complications from therapy, and managing patients deemed to be at high risk for treatment-related toxicity. CGA is a multidisciplinary, in-depth evaluation that assesses the objective health of the older adult while evaluating multiple domains, which may affect cancer prognosis and treatment choices. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines providing specific practical framework for the use of CGA when evaluating older adults with cancer.